Publication Name	World Journal of Gastroenterology
Manuscript ID	114057
Country	China

Category	Gastroenterology & Hepatology
Manuscript Type	Basic Study
Article Title	Cedrol ameliorates ulcerative colitis via myeloid differentiation factor 2-mediated inflammation suppression, with barrier restoration and microbiota modulation
Manuscript Source	Unsolicited Manuscript
All Author List	Yi-Qing Zhao, Yu Zhang, Yan Qin, Rui-Ya Zhang and Jun-Ping Wang
Funding Agency and Grant Number	Funding Agency Grant Number Provincial Key Cultivation Laboratory for Digestive Disease Research No. 2021SYS13 Shanxi Province’s “Si Ge Yi Pi” Science and Technology Driven Medical Innovation Project No. 2021MX03 Shanxi Provincial Basic Research Program No. 202403021222423
Corresponding Author	Jun-Ping Wang, Chief Physician, MD, Professor, Department of Gastroenterology, Shanxi Provincial People’s Hospital Affiliated to Shanxi Medical University, No. 29 Shuangtasi Street, Taiyuan 030012, Shanxi Province, China. wangjp8396@sxmu.edu.cn
Key Words	Cedrol; Ulcerative colitis; Toll-like receptor 4; Myeloid differentiation factor 2; Signaling pathways; Gut microbiota
Core Tip	Therapeutics to treat ulcerative colitis (UC) must be effective and safe. The natural compound cedrol (CE) possesses anti-inflammatory and antioxidant properties. However, its therapeutic efficacy and mechanisms in UC remain unclear. We demonstrated that CE ameliorated dextran sulfate sodium-induced colitis in mice through multifaceted mechanisms: Attenuating inflammation; Promoting intestinal barrier repair; And restoring gut microbial homeostasis. Mechanistically, CE exerted its anti-inflammatory effects by functionally inhibiting the toll-like receptor 4/myeloid differentiation factor 2 complex, thereby inhibiting the activation of proinflammatory signaling pathways. These findings highlighted the potential of CE as a promising therapeutic agent for UC.
Citation	Zhao YQ, Zhang Y, Qin Y, Zhang RY, Wang JP. Cedrol ameliorates ulcerative colitis via myeloid differentiation factor 2-mediated inflammation suppression, with barrier restoration and microbiota modulation. World J Gastroenterol 2025; In press

Received	2025-09-11 07:47
Peer-Review Started	2025-09-11 07:47
To Make the First Decision
Return for Revision	2025-10-22 09:06
Revised	2025-11-03 18:24
Second Decision	2025-11-18 01:39
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-11-18 09:19
Articles in Press	2025-11-18 09:19
Publication Fee Transferred	2025-11-04 01:48
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com